ES2609352T3 - Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos - Google Patents

Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos Download PDF

Info

Publication number
ES2609352T3
ES2609352T3 ES12816671.7T ES12816671T ES2609352T3 ES 2609352 T3 ES2609352 T3 ES 2609352T3 ES 12816671 T ES12816671 T ES 12816671T ES 2609352 T3 ES2609352 T3 ES 2609352T3
Authority
ES
Spain
Prior art keywords
factors
immunoglobulins
cytokines
antibacterial
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12816671.7T
Other languages
English (en)
Inventor
Alberto Bartorelli
Maria Rosa Gobbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innomed S A
Innomed Sa
Original Assignee
Innomed S A
Innomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT002443A external-priority patent/ITMI20112443A1/it
Priority claimed from IT002445A external-priority patent/ITMI20112445A1/it
Priority claimed from IT002440A external-priority patent/ITMI20112440A1/it
Priority claimed from IT002433A external-priority patent/ITMI20112433A1/it
Priority claimed from IT002446A external-priority patent/ITMI20112446A1/it
Priority claimed from IT002441A external-priority patent/ITMI20112441A1/it
Priority claimed from IT002435A external-priority patent/ITMI20112435A1/it
Priority claimed from IT002432A external-priority patent/ITMI20112432A1/it
Priority claimed from IT002439A external-priority patent/ITMI20112439A1/it
Application filed by Innomed S A, Innomed Sa filed Critical Innomed S A
Application granted granted Critical
Publication of ES2609352T3 publication Critical patent/ES2609352T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/206—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

Una combinación de citoquinas, factores de crecimiento, factores quimiotácticos, factores estimulantes de células madre, proteínas del complemento, inmunoglobulinas y factores antibacterianos/antivíricos, que consiste esencialmente en: Citoquinas (pg/mg):**Tabla** Factores de crecimiento (pg/mg):**Tabla** Factores estimulantes de células madre (pg/mg):**Tabla** Factores quimiotácticos (pg/mg):**Tabla** Factores antibacterianos/antivíricos (μg/mg):**Tabla** Proteínas del complemento (pg/mg):**Tabla** Inmunoglobulinas (mg/mg):**Fórmula** caracterizada en que está en forma de polvo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
Ejemplo 9 – Tratamiento de alopecia
La alopecia se puede prevenir y tratar eficazmente con PMF Ab, preferiblemente aplicando en sucesión una primera 5 composición tópica que actúa sobre el bulbo piloso en la fase catágena y una segunda composición tópica que estimula la fase anágena de recrecimiento del pelo.
La primera formulación tópica comprende como principios activos resina de aceite de capsicum, vitamina PP y cafeína además de excipientes convencionales. La segunda composición, que se va a aplicar al cuero cabelludo de
10 15 a 30 minutos después de la aplicación de la primera composición, comprende PMF Ab parcialmente en forma libre y parcialmente encapsulada en microesferas y otros ingredientes seleccionados de sericina, extracto de aloe vera, cafeína, melatonina y pantenol. A continuación, se describen ejemplos de formulaciones adecuadas:
1 pretratamiento
15 Resina de aceite de capsicum al 0,05% Vitamina PP al 0,20% Cafeína al 0,01% excipientes cs
20 2 tratamiento
P.M.F.
Ab al 10%
P.M.F.
Ab microencapsulado al 2,5% Sericina al 1,00% Aloe al 1,00%
25 Pantenol al 0,20% Melatonina al 0,005% Cafeína al 0,01% excipientes cs
30 Las formulaciones se ensayaron clínicamente en 30 casos de pérdida de pelo recurrente (telógena), especialmente en primavera y otoño. La pérdida de pelo se ha prevenido en el 88% de los hombres y el 75% de las mujeres.
En 20 pacientes sometidos a quimioterapia (mujeres con cáncer de mama), solo el 12% de las pacientes perdió el pelo, el 20% tuvieron el pelo más fino, pero no se cayó, en todos los casos sin efectos adversos.
35 Las formulaciones también se ensayaron en 10 pacientes con pérdida de pelo aguda, 10 pacientes con pérdida de pelo crónica, 5 pacientes con alopecia areata, 40 pacientes con alopecia androgenética y 7 pacientes con alopecia cicatricial
40 En pérdida de pelo aguda, la respuesta a la terapia de pacientes, 8 mujeres y 2 hombres, fue variable.
Después de dos meses de aplicación del producto, una vez al día, se detectó una clara reducción den la pérdida de pelo en 8 pacientes (7 mujeres – 1 hombre) con una recuperación modesta en solo un caso (hombre) en el tercer mes de terapia mientras que en los dos casos restantes (respectivamente, un hombre y una mujer), la situación no
45 cambió.
En la pérdida de pelo crónica, de los 10 casos tratados (9 mujeres y 1 hombre) 8 pacientes tuvieron una disminución después de dos meses de terapia. Dos pacientes no respondieron a la terapia.
50 En alopecia areata todos los sujetos tratados (5 pacientes, 3 mujeres y 2 hombres) tuvieron poca o ninguna respuesta después de dos meses de terapia.
Se trataron 40 sujetos (30 hombres y 10 mujeres) afectados por alopecia androgenética. Después de dos meses de terapia, una reducción en la pérdida de peso y mejora en el aspecto del pelo, cuantificable con un mayor diámetro 55 del barril, mayor volumen y mayor brillo del pelo en 30 de los casos tratados.
En los otros 10 casos, el estado clínico ha permanecido sin cambiar.
En 7 casos de alopecia cicatricial (4 mujeres y 3 hombres), en los que también había una reacción inflamatoria de la 60 piel con una sensación fuerte de picor, la respuesta fue sorprendente después de un mes de terapia.
Ha habido una disminución e incluso desaparición del picor, atenuación de la forma irritante cutánea y una estabilización de la alopecia.
14

Claims (1)

  1. imagen1
    imagen2
ES12816671.7T 2011-12-30 2012-12-27 Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos Active ES2609352T3 (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
IT002433A ITMI20112433A1 (it) 2011-12-30 2011-12-30 Composizioni per la terapia orale adiuvante dell'anoressia comprendenti anticorpi, antibatterici, fattori di crescita e citochine
ITMI20112445 2011-12-30
IT002446A ITMI20112446A1 (it) 2011-12-30 2011-12-30 Composizione per la terapia delle lesioni della mucosa orale
ITMI20112439 2011-12-30
ITMI20112441 2011-12-30
IT002441A ITMI20112441A1 (it) 2011-12-30 2011-12-30 Composizioni comprendenti fattori di crescita, fattori chemiotattici e antibatterici/antivirali, immunoglobuline e citochine per la terapia della enterocolite acuta necrotizzante (nec) nei prematuri e nei neonati a termine e per la prevenzione delle
ITMI20112443 2011-12-30
IT002443A ITMI20112443A1 (it) 2011-12-30 2011-12-30 Composizioni orali per la terapia dell'osteoporosi comprendenti fattori di crescita, citochine antibatterici e anticorpi
IT002440A ITMI20112440A1 (it) 2011-12-30 2011-12-30 Formulazioni contenenti citochine, fattori di crescita, chemiotattici, antibatterici ed eventualmente immunoglobuline e complemento, per la terapia topica delle lesioni corneali
IT002435A ITMI20112435A1 (it) 2011-12-30 2011-12-30 Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi
IT002439A ITMI20112439A1 (it) 2011-12-30 2011-12-30 Composizioni per la terapia del dolore neuropatico per via orale comprendenti citochine, fattori di crescita, rna, antibatterici e anticorpi
IT002445A ITMI20112445A1 (it) 2011-12-30 2011-12-30 Uso di citochine, fattori di crescita, fattori antibatterici e anticorpi, per la terapia topica di ulcere, piaghe e ustioni cutanee
ITMI20112432 2011-12-30
ITMI20112446 2011-12-30
ITMI20112433 2011-12-30
ITMI20112440 2011-12-30
ITMI20112435 2011-12-30
IT002432A ITMI20112432A1 (it) 2011-12-30 2011-12-30 Kit per il trattamento e la prevenzione dell'alopecia
PCT/EP2012/076962 WO2013098333A1 (en) 2011-12-30 2012-12-27 Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors

Publications (1)

Publication Number Publication Date
ES2609352T3 true ES2609352T3 (es) 2017-04-19

Family

ID=47598771

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12816671.7T Active ES2609352T3 (es) 2011-12-30 2012-12-27 Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos

Country Status (7)

Country Link
US (2) US9555084B2 (es)
EP (1) EP2797609B1 (es)
JP (1) JP6139562B2 (es)
DK (1) DK2797609T3 (es)
ES (1) ES2609352T3 (es)
RU (1) RU2642650C2 (es)
WO (1) WO2013098333A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173087A1 (en) 2011-12-30 2017-05-31 Innomed S.A. Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors
US10517931B2 (en) * 2013-01-17 2019-12-31 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
ITUB20160137A1 (it) * 2016-02-04 2017-08-04 Innomed S A Processo di estrazione da colostro
US12264333B2 (en) 2018-09-20 2025-04-01 Mystem Biotechnologies Inc. Colostrum derived stem cells, neural differentiation, compositions and supplements for enhancing mammalian health
AU2020394215A1 (en) * 2019-11-27 2022-06-09 Plakous Therapeutics, Inc. Acellular placental therapies for necrotizing enterocolitis
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물
EP3936110B1 (en) * 2020-07-07 2022-08-31 Dr. Kurt Wolff GmbH & Co. KG Treatment of seasonal hair thinning
US11318187B1 (en) * 2021-09-02 2022-05-03 Bjorn Eek Treatment of internal disc disruption and connective tissue injuries

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460135A1 (fr) * 1979-07-02 1981-01-23 Liotet Serge Composition a usage externe a base de colostrum
FR2487676A1 (fr) 1980-07-29 1982-02-05 Oraa Ste Civile Procede d'obtention d'extrait sec de colostrum
FR2627386A1 (fr) * 1988-02-22 1989-08-25 Serge Liotet Composition a usage externe destinee a l'administration oculaire
FR2628973B1 (fr) * 1988-03-25 1990-11-16 Gattefosse Ets Sa Composition cosmetique ou pharmaceutique a usage cutane, et procede pour la preparation d'une telle composition
CA2147598A1 (en) 1992-11-03 1994-05-11 Stryker Corporation Op-3-induced morphogenesis
US5750149A (en) 1993-01-26 1998-05-12 Horse Vitality Ltd Pharmaceutical and dermocosmetic compositions containing equine colostrum
EP0711171B1 (en) 1993-06-23 2002-09-04 Novatreat Oy A pharmaceutical or cosmetic composition comprising a colostrum fraction and its medical use
EP0743060B1 (en) 1995-04-28 2002-11-13 Sara Lee/DE N.V. Use of dental-care products comprising bovine colostrum
US6498236B1 (en) 1996-08-30 2002-12-24 Upfront Chromatography A/S Isolation of immunoglobulins
PL185442B1 (pl) 1996-10-03 2003-05-30 Georgiades Biotech Ltd Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie
IT1290347B1 (it) 1997-02-18 1998-10-22 Horse Vitality Ltd Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento della caduta dei capelli
IT1291340B1 (it) 1997-05-09 1999-01-07 Vander Way Limited Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale
ATE322275T1 (de) 1998-06-10 2006-04-15 Albert B Crum Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
JP2000159687A (ja) 1998-11-24 2000-06-13 Snow Brand Milk Prod Co Ltd 非有益腸内微生物定着阻止剤
WO2006029494A1 (en) 2004-09-14 2006-03-23 Nexcell Biosciences Inc. Extraction of growth and differentiating factors from colostrum
EP1789073A4 (en) * 2004-09-14 2011-06-08 Nexcell Biosciences Inc ISOLATION OF GROWTH AND DIFFERENTIATION FACTORS FROM COLOSTRUM
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
WO2007128737A2 (en) * 2006-05-04 2007-11-15 Alma Mater Studiorum - Universita Di Bologna Method and device to fractionate stem cells
CN106139124A (zh) * 2006-07-03 2016-11-23 让-保罗·佩罗丹 抗菌剂组合物及其用途
US20100068213A1 (en) 2007-02-20 2010-03-18 N.V. Nutricia Selected colostrum for treatment of intestinal barrier function disorders
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ITMI20092069A1 (it) * 2009-11-25 2011-05-26 Biofer Spa Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
NL2004099C2 (en) 2010-01-15 2011-07-18 Friesland Brands Bv Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof.
IT1405998B1 (it) 2010-12-09 2014-02-06 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
EP3173087A1 (en) 2011-12-30 2017-05-31 Innomed S.A. Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors

Also Published As

Publication number Publication date
EP2797609A1 (en) 2014-11-05
DK2797609T3 (en) 2017-01-09
US20140369957A1 (en) 2014-12-18
EP2797609B1 (en) 2016-10-05
US10098927B2 (en) 2018-10-16
WO2013098333A1 (en) 2013-07-04
JP6139562B2 (ja) 2017-05-31
US20170087213A1 (en) 2017-03-30
RU2014128297A (ru) 2016-02-20
US9555084B2 (en) 2017-01-31
JP2015506932A (ja) 2015-03-05
RU2642650C2 (ru) 2018-01-25

Similar Documents

Publication Publication Date Title
ES2609352T3 (es) Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos
Tallon et al. Permanent chemotherapy-induced alopecia: case report and review of the literature
MXPA04001231A (es) Composiciones topicas para aplicar y no enjuagar que contiene derivados seleccionados del acido pantotenico.
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
JP2005508936A5 (es)
CN1674863B (zh) 防止老化用组合物
JP2017537936A5 (es)
WO2013039597A2 (en) Method for enhancing the growth and fullness of hair
MX388073B (es) Composición farmacéutica, preparación y usos de la misma.
JP2020525460A5 (es)
US20150265526A1 (en) Topical composition for the cosmetic treatment of the human skin
US20120064174A1 (en) Method for stimulating hair growth
RU2011122458A (ru) Терапевтическое, пищевое или косметическое применение соединений со специфической антиапоптозной активностью для каспазы-3 и композиции, содержащие такие соединения
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
SI3057664T1 (en) Use of a composition for the pigmentation of hair and hairs
CN105579020A (zh) 包含鞘氨醇的制剂
ES2765486T3 (es) Composición para prevenir la pérdida de cabello o promover el crecimiento de cabello, que contiene derivado de ácido oleanólico y sal farmacéuticamente aceptable del mismo
Gupta et al. Do non-prescription products help in managing androgenic alopecia?
ES2879369T3 (es) Tratamiento tópico para prevenir y mitigar la citotoxicidad cutánea debido a terapia con inhibidores de tirosina quinasa
KR20160119690A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
ES2749645T3 (es) Loción contra la caída del cabello
FR3080765B1 (fr) Composition comprenant de l'acide alpha-lipoique ou l'un de ses sels, un derive de vitamine c et de l'acide hyaluronique et son utilisation
ES2541379A1 (es) Cosmética natural de bellota
DE202007012586U1 (de) Bockshornkleesamenextrakt
CN104432070A (zh) 一种改善皮肤水分的保健食品